736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies von Moser, Justin C, Sullivan, Ryan, Taylor, Matthew H, Puzanov, Igor, Falchook, Gerald S, Sznol, Mario, Paton, Virginia E, Chonzi, David, Garofalo, Brage, Sonnemann, Mark, Uppal, Hirdesh, Barton, Jeremy, McQueen, Beatrice Y, Ring, Aaron M, Kluger, Harriet

Volltext